The QL1706 Combined With Chemotherapy and Either Cetuximab or Bevacizumab in Potentially Resectable Colorectal Cancer Patients With Liver Metastases

Inclusion Criteria:

• Has signed a written informed consent form and voluntarily participates in this study;
• Age: 18-75 years old, regardless of gender;
• Histologically or cytologically confirmed colorectal adenocarcinoma with liver metastases, initially unresectable but potentially resectable as assessed by a multidisciplinary team (MDT), without other definite extrahepatic distant metastases;
• No prior systemic treatment;
• Known RAS and BRAF status;
• No contraindications to liver surgery;
• At least one measurable lesion according to RECIST 1.1;
• ECOG performance status: 0-1;
• Expected survival time \> 12 weeks;
• Sufficient organ and bone marrow function.

Exclusion Criteria:

• Active autoimmune diseases requiring systemic treatment occurring within 2 years before enrollment.
• Previous receipt of immune checkpoint inhibitors, including: anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, etc.
• Previous receipt of targeted drugs targeting epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), or their receptors (VEGFR), including bevacizumab, cetuximab, panitumumab, aflibercept, regorafenib, anlotinib, etc.
• Definite extrahepatic distant metastatic lesions.
• Unresectable primary tumor.
• HIV infection, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation (except corneal transplantation).
• Previous or concurrent other malignant tumors within 5 years;
• Accompanying pleural effusion, pericardial effusion, or ascites that is uncontrollable and requires drainage.
• Known active pulmonary tuberculosis, radiation pneumonitis, drug-induced pneumonia, or other diseases, symptoms, or signs causing severe impairment of lung function.